51成人动漫

This year's Genitourinary Cancers Symposium featured multiple studies on established therapies and drugs in development for bladder cancer, including antibody-drug conjugates (ADCs), immune checkpoint inhibitors, and tyrosine kinase inhibitors (TKIs).

In this exclusive video, , professor of medicine and urology at the Yale School of Medicine in New Haven, Connecticut, discusses the primary analysis of cohort 2 of the , which analyzed sacituzumab govitecan (Trodelvy) in platinum-ineligible patients with metastatic urothelial cancer (UC) who had progressed on a checkpoint inhibitor.

Following is a transcript of his remarks:

We've seen a virtual explosion of new treatments for bladder cancer, and these include ADCs, checkpoint therapy, and TKIs. And there are actually two FDA-approved ADCs for refractory urothelial carcinoma -- enfortumab vedotin [Padcev], as well as sacituzumab govitecan.

Now the question is, can we start moving these agents up earlier in the course of resistant urothelial carcinoma?

So the second cohort of the TROPHY-U-01 study was designed to evaluate sacituzumab govitecan in those patients who were not eligible to receive cisplatin-based chemotherapy and who had had a prior checkpoint inhibition treatment.

Overall, we found that when we administered sacituzumab at 10 mg/kg, on days 1 and 8, that the response rates were approximately 32% in these patients. No new safety signals were identified. The major side effects that we see are neutropenia as well as diarrhea.

And so further study is warranted in this group of patients evaluating sacituzumab govitecan. Also, additionally, in those patients who did not receive prior chemotherapy or prior enfortumab vedotin therapy, response rate was somewhat higher, 52%. But again, that's a small number of patients, so that needs to be interpreted with caution.

So in summary, sacituzumab govitecan has activity in patients who are ineligible to receive cisplatin-based chemotherapy or platinum-based chemotherapy. And further studies are warranted in this sub-disease state.

Comment